Structure-based design of inhibitors of purine nucleoside

1034

J . Med. Chem. 1994,37, 1034

Additions and Corrections 1993, Volume 36

Mark D. Erion, S h r i Niwas, J e r r y D. Rose, Subramaniam Ananthan, Mark Allen, John A. Secrist, 111, Y.Sudhakar Babu, Charles E.Bugg, Wayne C. Guida, Steven E. Ealick, and John A. Montgomery.: Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 3. 9-Arylmethyl Derivatives of 9-Deazaguanine Substituted on the Methylene Group . Page 3773. The caption for Figure 1should read: Stereo comparison of the binding of 4f (red) and 4h (green) with that of 9-benzyl-9-deazaguanine (blue) in the active site of PNP as determined by X-ray crystallography. Page 3783. In the first paragraph, the heading should 3,2-d]pyrimidinread "3-(2-Amino-4-oxo-3H,5H-pyrrolo[ 7-yl)-3-cyclohexylpropano1(23)".

Daljit S.Dhanoa,' Scott W. Bagley, Raymond S. L. Chang, Victor J. Lotti, Tsing-Bau Chen, Salah D. Kivlighn, Gloria J. Zingaro, Peter K. S.Siegl, Arthur A. Patchett, and William J. Greenlee: Non-Peptide Angiotensin I1 Receptor Antagonists. 2.l Design, Synthesis, and Biological Activity of N-Substituted (Phenylamino)phenylacetic Acids and Acyl Sulfonamides2. Page 4241. The structure of compound 19 in Scheme V is drawn incorrectly. The correct structure is

Me

19

0022-262319411837-1034$04.50/0 0 1994 American Chemical Society